ClinicalTrials.gg
Active, not recruitingNCT06706622MASCOTUpdated Oct 14, 2026

A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)

A Phase 3 interventional study of Amlenetug and Placebo in Multiple System Atrophy, sponsored by H. Lundbeck A/S. Active, not recruiting at 74 sites in 10 countries. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment

Updated Oct 14, 202665 sites added65 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
401
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 90 studies in Multiple System Atrophy with a site in United States — 21 open to participants now, 32 under way, 1 of them phase 3. Multiple System Atrophy · United States.

Enrollment
6th of 57
401 · median 35
Started
2024
with 3 others
Phase 3
7 of 90
none open now
Primary completion
2028-02
later than 24 of 31 live
Registered
82nd of 90
by date
Lead sponsor
3 of 90
H. Lundbeck A/S

Among the 90 studies in Multiple System Atrophy with a site in United States, this one is the 6th largest by enrollment of the 57 interventional ones that give a count, is one of 4 that started in 2024, is one of 7 in phase 3, reaches primary completion later than 24 of the 31 other live ones, and was the 82nd registered.

Multiple System Atrophy

207 studies on the registry are indexed under Multiple System Atrophy; 73 are open to participants now.

Browse Multiple System Atrophy studies →

Open to participants now

21 of the 90 studies in Multiple System Atrophy with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 57 Multiple System Atrophy studies recruiting now, 24 (42%) set no upper age limit and 11 (19%) stop at 75 or younger; 7 take children under 18; 18 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies in Multiple System Atrophy with a site in United States, or all of them as a file.
02

Study summary

The main goal of this trial is to evaluate the efficacy and safety of amlenetug for the treatment of participants with Multiple System Atrophy (MSA).

Read the detailed description

This study will consist of a screening period of 10 days up to 6 weeks, a 72-week placebo-controlled period (PCP), and will include a 72-week optional open-label treatment extension (OLE) period. Participants in the PCP will be randomized to amlenetug or placebo. All participants entering the OLE will receive amlenetug during the OLE. Participants will receive intravenous infusions approximately every 4 weeks during both the PCP and OLE.

03

Conditions studied

  • Multiple System Atrophy

Keywords

  • Lu AF82422
  • MSA
  • Neurodegenerative Disorder
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • The participant has a diagnosis of clinically established multiple system atrophy parkinsonian type (MSA-P) or multiple system atrophy cerebellar type (MSA-C), or clinically probable MSA-P or MSA-C, according to the 2022 Movement Disorders Society (MDS) criteria for the diagnosis of MSA at the Screening Visit.
  • The participant had onset of motor MSA symptoms (that is, parkinsonian and/or cerebellar) within 5 years prior to the Screening Visit in the judgement of the investigator.
  • The participant has an anticipated survival of >3 years, in the opinion of the investigator, at the Screening Visit.
  • The participant has suitable peripheral venous access for medicinal product (IMP) administration and blood sampling.
  • The participant has an UMSARS Part I score ≤16 (omitting item 11 on sexual function) at the Screening Visit.

Exclusion Criteria:

  • The participant has previously been dosed with amlenetug.
  • The participant has taken any active IMP within 3 months or 5 half lives of that product, whichever is longer, prior to the first dose of IMP.
  • The participant has 2 or more first degree relatives with a history of MSA.
  • The participant, if of MSA-P subtype, has unexplained anosmia (not explained by other common causes such as allergic rhinitis or smoking, nasal structural lesions, or nasal surgery) on olfactory testing at the Screening Visit.
  • The participant has evidence (clinically or on magnetic resonance imaging (MRI)) and/or history of any disease or condition other than MSA, that is, in the investigator's opinion, likely to affect CNS functioning, e.g., serious neurological disorder, other intracranial or systemic disease.
  • The participant has a current diagnosis of movement disorders that could mimic MSA, e.g., Parkinson's disease, dementia with Lewy bodies, essential tremor, progressive supranuclear palsy, spinocerebellar ataxia, spastic paraparesis, corticobasal degeneration, or vascular, pharmacological, or post-encephalitic parkinsonism, per investigator discretion. Participants who have previously been incorrectly diagnosed with Parkinson's disease will not be excluded.

Other protocol-defined inclusion and exclusion criteria apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
401 participants (actual)

Study arms

  • Experimental
    Amlenetug

    Participants will receive amlenetug by intravenous infusion

    Drug: Amlenetug

  • Placebo comparator
    Placebo

    Participants will receive commercially available saline solution for infusion

    Drug: Placebo

Interventions

  • Solution for infusion

    Also known as: Lu AF82422

  • DrugPlacebo

    Commercially available saline solution

06

What researchers measure

Primary outcomes

  1. Rest of the World (RoW; All Countries Except European Union [EU] and Japan [JP]) Regional-specific Outcome Measure: Mortality-adjusted Clinical Progression

    Mortality-adjusted clinical progression will be assessed by the composite endpoint modified Unified Multiple System Atrophy Rating Scale (mUMSARS) score and time-to-death (any cause).

    Time frame: Baseline up to Week 72

  2. EU and JP Regional-specific Outcome Measure: Mortality-adjusted Clinical Progression

    Mortality-adjusted clinical progression will be assessed by the composite endpoint Unified Multiple System Atrophy Rating Scale (UMSARS) Total Score (TS) and time-to-death (any cause).

    Time frame: Baseline up to Week 72

Secondary outcomes

  1. RoW Regional-specific Outcome Measure: Mortality-adjusted Clinical Progression

    Mortality-adjusted clinical progression will be assessed by the composite endpoint UMSARS TS and time-to-death (any cause).

    Time frame: Baseline up to Week 72

  2. EU and JP Regional-specific Outcome Measure: Change from Baseline in UMSARS TS

    Time frame: Baseline, Week 72

  3. RoW Regional-specific Outcome Measure: Change from Baseline in UMSARS TS

    Time frame: Baseline, Week 72

  4. Mortality-adjusted Clinical Progression

    Mortality-adjusted clinical progression will be assessed by the composite endpoint UMSARS Part I and time-to-death (any cause).

    Time frame: Baseline up to Week 72

  5. Mortality-adjusted Clinical Progression

    Mortality-adjusted clinical progression will be assessed by the composite endpoint UMSARS Part II and time-to-death (any cause).

    Time frame: Baseline up to Week 72

  6. Change from Baseline in mUMSARS Score

    Time frame: Baseline, Week 72

  7. Change from Baseline in UMSARS Part I Score

    Time frame: Baseline, Week 72

  8. Change from Baseline in UMSARS Part II Score

    Time frame: Baseline, Week 72

  9. Change from Baseline in Clinical Global Impression - Severity of Illness (CGI-S) Score

    Time frame: Baseline, Week 72

  10. Change from Baseline in Patient Global Impression - Severity of Illness (PGI-S) Score

    Time frame: Baseline, Week 72

  11. Change from Baseline in Observer-reported Global Impression-Severity of Illness (OGI-S) Score

    Time frame: Baseline, Week 72

  12. Change from Baseline in UMSARS Part IV Score

    Time frame: Baseline, Week 72

  13. Change from Baseline in Schwab and England Activities of Daily Living (SE-ADL) Score

    Time frame: Baseline, Week 72

  14. Change from Baseline in UMSARS Part I Item 1: Speech Score

    Time frame: Baseline, Week 72

  15. Time to Disability

    Time frame: Baseline up to Week 72

  16. Change from Baseline in EuroQol 5-dimensions, 5-levels (EQ-5D-5L) Domain Score

    Time frame: Baseline, Week 72

  17. Change from Baseline in EQ-5D-5L Visual Analog Scale (VAS) Score

    Time frame: Baseline, Week 72

  18. Change from Baseline in Multiple System Atrophy Quality of Life (MSA-QoL) Questionnaire Domain Scores

    Time frame: Baseline, Week 72

  19. Combined Clinical Progression and Survival Score

    Time frame: Baseline, Week 72

  20. Time from Baseline to Death (Any Cause)

    Time frame: Baseline up to Week 72

  21. Number of Participants with an Absolute Increase in mUMSARS Score of <5, <7, and <9 points

    Time frame: Baseline to Week 72

  22. Number of Participants with an Absolute Increase in UMSARS TS of <16, <21, and <26 Points

    Time frame: Baseline to Week 72

  23. Percentage Change from Baseline in Brain Volume in Brain Regions of Interest (ROIs)

    Time frame: Baseline, Week 72

  24. Area Under the Curve (AUC) of amlenetug

    Time frame: Baseline up to Week 72

  25. Maximum Observed Concentration (Cmax) of Amlenetug

    Time frame: Baseline up to Week 72

  26. Number of Participants with Treatment-emergent Adverse Events (TEAEs)

    Time frame: Day 1 up to Week 144

  27. Number of Participants with Anti-amlenetug Antibodies (ADAs)

    Time frame: Baseline up to Week 144

07

Study locations

74 sites
  • Mayo Clinic - Vascular Center - Arizona
    Phoenix, Arizona 85054-4502, United States
  • University of Arkansas for Medical Sciences (UAMS) - Medical Center
    Little Rock, Arkansas 72205-7101, United States
  • University of California San Francisco - Sandler Neurosciences Center
    San Francisco, California 94158-0003, United States
  • CenExel CBH - CenExel Rocky Mountain Clinical Research (CenExel RMCR) (Rocky Mountain Movement Di...
    Englewood, Colorado 80113-2776, United States
  • Yale New Haven Health System
    New Haven, Connecticut 06519-1304, United States
  • Parkinson's Disease and Movement Disorders Center of Boca Raton
    Boca Raton, Florida 33486-2359, United States
  • University of Florida-College of Medicine - Gainesville
    Gainesville, Florida 32610-3003, United States
  • Indiana University (IU) Health-Senior Health Center
    Indianapolis, Indiana 46202-1476, United States
  • Johns Hopkins University School of Medicine - The Johns Hopkins Multiple Sclerosis (MS) Center
    Baltimore, Maryland 21287-0005, United States
  • Brigham and Women's Hospital (BWH)
    Boston, Massachusetts 02115, United States
  • Harvard Medical School - Beth Israel Deaconess Medical Center (BIDMC) - West Campus
    Boston, Massachusetts 02215-5321, United States
  • QUEST Research Institute
    Farmington, Michigan 48334-2980, United States
  • Mayo Clinic - Children's Center - Rochester
    Rochester, Minnesota 55905-0001, United States
  • University of Nebraska Medical Center (UNMC) - The Lied Transplant Center
    Omaha, Nebraska 68198-3285, United States
  • NYU Langone Health (NYU Langone Medical Center)
    New York, New York 10016, United States
  • Columbia University Irving Medical Center - The Neurological Institute of New York
    New York, New York 10032-3726, United States
  • Cleveland Clinic - Neurological Institute - Cerebrovascular Center
    Cleveland, Ohio 44195-0001, United States
  • University of Pennsylvania - Penn Comprehensive Neuroscience Center
    Philadelphia, Pennsylvania 19107-6103, United States
  • University of Pittsburgh Medical Center-Magee-Womens Hospital (MWH)
    Pittsburgh, Pennsylvania 15213-3108, United States
  • Vanderbilt University Medical Center (VUMC) - Vanderbilt Orthopaedic Institute-Nashville
    Nashville, Tennessee 37232-0001, United States
  • University of Texas Southwestern Medical Center (UT Southwestern Medical Center)
    Dallas, Texas 75390-7208, United States
  • Baylor College of Medicine (BCM)
    Houston, Texas 77030-3411, United States
  • Inland Northwest Research (INWR)
    Spokane, Washington 99202-1342, United States
  • University of New South Wales-Liverpool Hospital - Liverpool Cancer Therapy Centre
    Liverpool, New South Wales 2170, Australia
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • Gold Coast University Hospital (GCUH) (Gold Coast Hospital)
    Southport, Queensland 4215, Australia
  • The Alfred Hospital
    Melbourne, Victoria 3004, Australia
  • The Ottawa Hospital - Centre for Rehabilitation Research and Development (CRRD) (The Institute fo...
    Ottawa, Ontario K1H 8M2, Canada
  • University Health Network-Toronto Western Hospital - Krembil Neuroscience Centre (KNC)
    Toronto, Ontario M5T 2S8, Canada
  • Centre Hospitalier Universitaire de Rennes-Hopital Pontchaillou
    Rennes, Brittany Region 35033, France
  • Centre Hospitalier Universitaire de Lille (CHU Lille) - Centre Regional de Pharmacovigilance (CRPV)
    Lille, Hauts-de-France 59045, France
  • Centre Hospitalier Universitaire (CHU) de Bordeaux - Groupe Hospitalier Pellegrin - Tripode
    Bordeaux, New Aquitaine 33000, France
  • Centre Hospitalier Universitaire de Montpellier (CHU Montpellier)
    Montpellier, Occitanie 34295, France
  • Centre Hospitalier Universitaire de Toulouse-Hopital Purpan
    Toulouse, Occitanie 31300, France
  • AP-HM- Hôpital de La Timone
    Marseille, 13005, France
  • CHU de la Pitié-Salpêtrière
    Paris, 75651, France
  • Universitaetsklinikum Tuebingen - Universitaetsklinik fuer Psychiatrie und Psychotherapie
    Tübingen, Baden-Wurttemberg 72076, Germany
  • Universitaetsklinikum Erlangen - Psychiatrische und Psychotherapeutische Klinik
    Erlangen, Bavaria 91054, Germany
  • Curiositas Ad Sanum - Haag In Oberbayern
    Haag I.Ob, Bavaria 83527, Germany
  • Ludwig-Maximilians-Universitaet Muenchen (LMU) - Klinik und Poliklinik fuer Frauenheilkunde und G...
    Munich, Bavaria 81377, Germany
  • Universitaetsklinikum Muenster (UKM) - Medizinische Klinik A
    Münster, North Rhine-Westphalia 48149, Germany
  • Movement Disorders Clinic Beelitz-Heilstätten
    Beelitz-Heilstätten, 14547, Germany
  • Universita di Bologna - IRCCS Istituto delle Scienze Neurologiche di Bologna
    Bologna, 40123, Italy
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Centro Dino Ferrari
    Milan, 20122, Italy
  • Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
    Milan, 20133, Italy
  • Universita degli Studi della Campania "Luigi Vanvitelli" - Centro Cefalee
    Naples, 80138, Italy
  • Azienda Ospedaliero Universitaria Pisana - Stabilimento Ospedaliero di Santa Chiara - Istituto To...
    Pisa, 56126, Italy
  • Azienda Ospedaliera Universitaria OO.RR. San Giovanni di Dio e Ruggi d'Aragona - Scuola Medica Sa...
    Salerno, 84131, Italy
  • National Hospital Organization Higashinagoya National Hospital
    Nagoya, Aichi-ken 465-8620, Japan
  • Fujita Health University Hospital
    Toyoake-Shi, Aichi-ken 470-1192, Japan
  • Gifu University Hospital
    Gifu, Gifu 501-1194, Japan
  • Hokkaido University Hospital
    Sapporo, Hokkaido 060-8648, Japan
  • National Hospital Organization Sendai Nishitaga National Hospital
    Sendai, Miyagi 982-8555, Japan
  • Niigata University Medical and Dental Hospital
    Niigata, Niigata 951-8510, Japan
  • Saitama Medical University (SMU) - Moro Hospital
    Iruma-shi, Saitama 350-0495, Japan
  • Juntendo University-Juntendo University Hospital
    Bunkyō City, Tokyo-To 113-8431, Japan
  • National Center of Neurology and Psychiatry-National Center Hospital
    Kodaira-shi, Tokyo-To 187-8551, Japan
  • Keio University Hospital
    Shinjuku-Ku, Tokyo-To 160-8582, Japan
  • Tottori University Hospital
    Yonago-shi, Tottori 683-8504, Japan
  • Kyung Hee University Hospital
    Seoul, 02447, South Korea
  • Severance Hospital, Yonsei University Health System
    Seoul, 03722, South Korea
  • Samsung Medical Center
    Seoul, 06351, South Korea
  • Hospital Universitario Virgen del Rocio (HUVR) - Instituto de Biomedicina de Sevilla (IBIS)
    Seville, Seville 41013, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Clinic de Barcelona (Hospital Clinic i Provincial) - Institut Clinic de Neurociencies (ICN)
    Barcelona, 08036, Spain
  • Hospital de la Santa Creu I Sant Pau - Institut de Recerca de l'Hospital de la Santa Creu i Sant ...
    Barcelona, 08041, Spain
  • Universidad Autonoma de Madrid (UAM) - Hospital Universitario de La Princesa - Instituto de Inves...
    Madrid, 28006, Spain
  • Hospital Universitari i Politecnic La Fe de Valencia (Hospital La Fe Bulevar Sur)
    Valencia, 46026, Spain
  • Newcastle University - Clinical Ageing Research Unit (CARU)
    Newcastle upon Tyne, North East NE4 5PL, United Kingdom
  • Northern Care Alliance NHS Foundation Trust - Salford Royal Hospital (Hope Hospital)
    Salford, North West, United Kingdom M6 8HD, United Kingdom
  • Oxford University Hospitals NHS Foundation Trust-Oxford Centre for Functional MRI of the Brain (F...
    Oxford, South East OX3 9DU, United Kingdom
  • NHS Greater Glasgow and Clyde-Glasgow Clinical Research Facility - Queen Elizabeth University Hos...
    Glasgow, South Western Scotland G51 4TF, United Kingdom
  • Royal Devon University Healthcare NHS Foundation Trust - Royal Devon and Exeter Hospital (RD&E) -...
    Exeter, South West EX2 5PW, United Kingdom
  • University College London Hospitals NHS Foundation Trust-National Hospital for Neurology & Neuros...
    London, WC1N 3BG, United Kingdom
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Feb 2028, 38 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2024
First posted
Nov 26, 2024
StartActual
Dec 3, 2024
Primary completionEst.
Feb 17, 2028
CompletionEst.
Oct 25, 2029
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
65 sites added, 65 sites removed
Show 65 added (23 United States, 7 France, 7 Japan, 6 Germany, 6 Italy, 6 Spain, 6 United Kingdom, 2 Australia, 2 Canada)
  • Mayo Clinic - Vascular Center - Arizona · Phoenix, United States
  • University of Arkansas for Medical Sciences (UAMS) - Medical Center · Little Rock, United States
  • University of California San Francisco - Sandler Neurosciences Center · San Francisco, United States
  • CenExel CBH - CenExel Rocky Mountain Clinical Research (CenExel RMCR) (Rocky Mountain Movement Di... · Englewood, United States
  • Yale New Haven Health System · New Haven, United States
  • Parkinson's Disease and Movement Disorders Center of Boca Raton · Boca Raton, United States
  • University of Florida-College of Medicine - Gainesville · Gainesville, United States
  • Indiana University (IU) Health-Senior Health Center · Indianapolis, United States
  • Johns Hopkins University School of Medicine - The Johns Hopkins Multiple Sclerosis (MS) Center · Baltimore, United States
  • Brigham and Women's Hospital (BWH) · Boston, United States
  • Harvard Medical School - Beth Israel Deaconess Medical Center (BIDMC) - West Campus · Boston, United States
  • QUEST Research Institute · Farmington, United States
  • Mayo Clinic - Children's Center - Rochester · Rochester, United States
  • University of Nebraska Medical Center (UNMC) - The Lied Transplant Center · Omaha, United States
  • NYU Langone Health (NYU Langone Medical Center) · New York, United States
  • Columbia University Irving Medical Center - The Neurological Institute of New York · New York, United States
  • Cleveland Clinic - Neurological Institute - Cerebrovascular Center · Cleveland, United States
  • University of Pennsylvania - Penn Comprehensive Neuroscience Center · Philadelphia, United States
  • University of Pittsburgh Medical Center-Magee-Womens Hospital (MWH) · Pittsburgh, United States
  • Vanderbilt University Medical Center (VUMC) - Vanderbilt Orthopaedic Institute-Nashville · Nashville, United States
  • University of Texas Southwestern Medical Center (UT Southwestern Medical Center) · Dallas, United States
  • Baylor College of Medicine (BCM) · Houston, United States
  • Inland Northwest Research (INWR) · Spokane, United States
  • University of New South Wales-Liverpool Hospital - Liverpool Cancer Therapy Centre · Liverpool, Australia
  • Gold Coast University Hospital (GCUH) (Gold Coast Hospital) · Southport, Australia
  • The Ottawa Hospital - Centre for Rehabilitation Research and Development (CRRD) (The Institute fo... · Ottawa, Canada
  • University Health Network-Toronto Western Hospital - Krembil Neuroscience Centre (KNC) · Toronto, Canada
  • Centre Hospitalier Universitaire de Rennes-Hopital Pontchaillou · Rennes, France
  • Centre Hospitalier Universitaire de Lille (CHU Lille) - Centre Regional de Pharmacovigilance (CRPV) · Lille, France
  • Centre Hospitalier Universitaire (CHU) de Bordeaux - Groupe Hospitalier Pellegrin - Tripode · Bordeaux, France
  • …and 35 more on the registry record
Show 65 removed
  • Mayo Clinic · Scottsdale, United States
  • University of Arkansas for Medical Sciences · Little Rock, United States
  • University of California, San Francisco Neurosciences Clinical Research Unit · San Francisco, United States
  • CenExel Rocky Mountain Clinical Research, LLC · Englewood, United States
  • Yale New Haven Health · North Haven, United States
  • Parkinson's Disease And Movement Disorder Center Of Boca Raton · Boca Raton, United States
  • University of Florida Norman Fixel Institute for Neurological Diseases · Gainesville, United States
  • Indiana Health University · Indianapolis, United States
  • Johns Hopkins University School of Medicine · Baltimore, United States
  • Brigham and Women's Hospital · Boston, United States
  • Beth Israel Deaconess Medical Center · Boston, United States
  • QUEST Research Institute · Farmington Hills, United States
  • Mayo Clinic · Rochester, United States
  • University Nebraska Medical Center · Omaha, United States
  • NYU Medical Center - Dysautonomia center · New York, United States
  • Columbia University Medical Center - The Neurological Institute of New York · New York, United States
  • Cleveland Clinic - Neurological Institute · Cleveland, United States
  • University of Pennsylvania · Philadelphia, United States
  • University Of Pittsburgh · Pittsburgh, United States
  • Vanderbilt University Medical Center-Cognitive and Movement Disorders Group · Nashville, United States
  • University of Texas Southwestern Medical Center ¿ Multiple System Atrophy Clinic · Dallas, United States
  • Baylor College Of Medicine · Houston, United States
  • Inland Northwest Research · Spokane, United States
  • Liverpool Hospital - South Western Sydney Local Health District · Liverpool, Australia
  • Gold Coast Hospital · Southport, Australia
  • The Ottawa Hospital Research Institute · Ottawa, Canada
  • Toronto Western Hospital (TWH) · Toronto, Canada
  • Centre Hospitalier Universitaire (CHU) de Bordeaux - Groupe Hospitalier Pellegrin · Bordeaux, France
  • Centre Hospitalier Regional Universitaire de Lille - Hopital Roger Salengro · Lille, France
  • CHU - Hospital de la Timone · Marseille, France
  • …and 35 more on the registry record
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    65 sites added, 65 sites removed
    Show 65 added (23 United States, 7 France, 7 Japan, 6 Germany, 6 Italy, 6 Spain, 6 United Kingdom, 2 Australia, 2 Canada)
    • Mayo Clinic - Vascular Center - Arizona · Phoenix, United States
    • University of Arkansas for Medical Sciences (UAMS) - Medical Center · Little Rock, United States
    • University of California San Francisco - Sandler Neurosciences Center · San Francisco, United States
    • CenExel CBH - CenExel Rocky Mountain Clinical Research (CenExel RMCR) (Rocky Mountain Movement Di... · Englewood, United States
    • Yale New Haven Health System · New Haven, United States
    • Parkinson's Disease and Movement Disorders Center of Boca Raton · Boca Raton, United States
    • University of Florida-College of Medicine - Gainesville · Gainesville, United States
    • Indiana University (IU) Health-Senior Health Center · Indianapolis, United States
    • Johns Hopkins University School of Medicine - The Johns Hopkins Multiple Sclerosis (MS) Center · Baltimore, United States
    • Brigham and Women's Hospital (BWH) · Boston, United States
    • Harvard Medical School - Beth Israel Deaconess Medical Center (BIDMC) - West Campus · Boston, United States
    • QUEST Research Institute · Farmington, United States
    • Mayo Clinic - Children's Center - Rochester · Rochester, United States
    • University of Nebraska Medical Center (UNMC) - The Lied Transplant Center · Omaha, United States
    • NYU Langone Health (NYU Langone Medical Center) · New York, United States
    • Columbia University Irving Medical Center - The Neurological Institute of New York · New York, United States
    • Cleveland Clinic - Neurological Institute - Cerebrovascular Center · Cleveland, United States
    • University of Pennsylvania - Penn Comprehensive Neuroscience Center · Philadelphia, United States
    • University of Pittsburgh Medical Center-Magee-Womens Hospital (MWH) · Pittsburgh, United States
    • Vanderbilt University Medical Center (VUMC) - Vanderbilt Orthopaedic Institute-Nashville · Nashville, United States
    • University of Texas Southwestern Medical Center (UT Southwestern Medical Center) · Dallas, United States
    • Baylor College of Medicine (BCM) · Houston, United States
    • Inland Northwest Research (INWR) · Spokane, United States
    • University of New South Wales-Liverpool Hospital - Liverpool Cancer Therapy Centre · Liverpool, Australia
    • Gold Coast University Hospital (GCUH) (Gold Coast Hospital) · Southport, Australia
    • The Ottawa Hospital - Centre for Rehabilitation Research and Development (CRRD) (The Institute fo... · Ottawa, Canada
    • University Health Network-Toronto Western Hospital - Krembil Neuroscience Centre (KNC) · Toronto, Canada
    • Centre Hospitalier Universitaire de Rennes-Hopital Pontchaillou · Rennes, France
    • Centre Hospitalier Universitaire de Lille (CHU Lille) - Centre Regional de Pharmacovigilance (CRPV) · Lille, France
    • Centre Hospitalier Universitaire (CHU) de Bordeaux - Groupe Hospitalier Pellegrin - Tripode · Bordeaux, France
    • …and 35 more on the registry record
    Show 65 removed
    • Mayo Clinic · Scottsdale, United States
    • University of Arkansas for Medical Sciences · Little Rock, United States
    • University of California, San Francisco Neurosciences Clinical Research Unit · San Francisco, United States
    • CenExel Rocky Mountain Clinical Research, LLC · Englewood, United States
    • Yale New Haven Health · North Haven, United States
    • Parkinson's Disease And Movement Disorder Center Of Boca Raton · Boca Raton, United States
    • University of Florida Norman Fixel Institute for Neurological Diseases · Gainesville, United States
    • Indiana Health University · Indianapolis, United States
    • Johns Hopkins University School of Medicine · Baltimore, United States
    • Brigham and Women's Hospital · Boston, United States
    • Beth Israel Deaconess Medical Center · Boston, United States
    • QUEST Research Institute · Farmington Hills, United States
    • Mayo Clinic · Rochester, United States
    • University Nebraska Medical Center · Omaha, United States
    • NYU Medical Center - Dysautonomia center · New York, United States
    • Columbia University Medical Center - The Neurological Institute of New York · New York, United States
    • Cleveland Clinic - Neurological Institute · Cleveland, United States
    • University of Pennsylvania · Philadelphia, United States
    • University Of Pittsburgh · Pittsburgh, United States
    • Vanderbilt University Medical Center-Cognitive and Movement Disorders Group · Nashville, United States
    • University of Texas Southwestern Medical Center ¿ Multiple System Atrophy Clinic · Dallas, United States
    • Baylor College Of Medicine · Houston, United States
    • Inland Northwest Research · Spokane, United States
    • Liverpool Hospital - South Western Sydney Local Health District · Liverpool, Australia
    • Gold Coast Hospital · Southport, Australia
    • The Ottawa Hospital Research Institute · Ottawa, Canada
    • Toronto Western Hospital (TWH) · Toronto, Canada
    • Centre Hospitalier Universitaire (CHU) de Bordeaux - Groupe Hospitalier Pellegrin · Bordeaux, France
    • Centre Hospitalier Regional Universitaire de Lille - Hopital Roger Salengro · Lille, France
    • CHU - Hospital de la Timone · Marseille, France
    • …and 35 more on the registry record
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06706622
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Nov 26, 2024
Start date
Dec 3, 2024
Primary completion
Feb 17, 2028 (estimated)
Completion
Oct 25, 2029 (estimated)
Last update
Oct 14, 2026

Study contacts

Email contact via H. Lundbeck A/S
study director · H. Lundbeck A/S

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amlenetug

Start the discussion